+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Botanical Drug Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030- Product Image
Botanical Drug Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030- Product Image
New

Botanical Drug Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030

  • PDF Icon

    Report

  • 192 Pages
  • May 2025
  • Region: Global, United States
  • 360iResearch™
  • ID: 6083700
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Botanical Drug Market grew from USD 4.01 billion in 2024 to USD 4.30 billion in 2025. It is expected to continue growing at a CAGR of 6.99%, reaching USD 6.01 billion by 2030.

The botanical drug sector stands at a pivotal moment where ancient herbal knowledge converges with modern pharmaceutical innovation. In the wake of rising consumer demand for natural therapeutics and growing regulatory support, stakeholders across the value chain are accelerating research, development, and commercialization efforts. This executive summary outlines the key dynamics shaping the botanical drug market, delving into the strategic shifts, policy impacts, segmentation nuances, regional hotspots, and competitive landscape. By unpacking these dimensions, we aim to provide decision-makers with a comprehensive understanding of market drivers, challenges, and opportunities. Whether you are involved in research and development, regulatory affairs, manufacturing, or investment, these insights will support informed strategy formulation and foster sustainable growth in this rapidly evolving industry.

Transformative Shifts Reshaping the Botanical Drug Sector

Over the past decade, the botanical drug arena has undergone transformative shifts driven by advances in extraction technologies, breakthroughs in phytochemical analysis, and heightened collaboration between academic institutions and industry players. High-throughput screening methods now enable rapid identification of bioactive compounds from diverse sources, while novel delivery platforms-such as nanoemulsions and liposomal formulations-improve bioavailability and patient compliance. Regulatory pathways have also evolved, with health authorities streamlining guidelines for botanical new drug applications and offering clearer frameworks for clinical trial design.

Increasingly, strategic alliances have emerged between established pharmaceutical companies and dedicated botanical innovators, fostering co-development models that balance scientific rigor with agility. Simultaneously, the growing emphasis on sustainability has prompted supply chain actors to adopt eco-friendly cultivation and harvesting practices, ensuring consistent quality and traceability. As consumer preferences shift toward holistic wellness, botanical drugs are crossing over into adjacent sectors-such as nutraceuticals and functional foods-amplifying market potential and incentivizing further investment. These cumulative changes underscore a fundamental pivot toward integrated, evidence-based herbal therapeutics that can address complex health challenges.

Cumulative Impact of United States Tariffs in 2025

In 2025, the United States introduced updated tariff measures targeting key botanical imports, aiming to protect domestic growers and prioritize locally sourced raw materials. These duties, applied primarily to non-cultivated plant and fungal extracts, have led to recalibrated supply chains, with many companies relocating extraction facilities closer to North American agricultural hubs. While proponents argue that this policy enhances quality control and reduces carbon footprints, critics warn of increased production costs and potential bottlenecks in ingredient availability.

To mitigate cost pressures, several manufacturers have diversified their botanical portfolios by incorporating domestically cultivated seaweed and algae, which fall under preferential trade agreements. Others have entered toll-processing partnerships in neighboring countries to maintain access to specialized corals and mushrooms without incurring full tariff burdens. Concurrently, organizations are accelerating efforts to develop yeast-derived analogs of rare fungal compounds, leveraging fermentation science to bypass import restrictions. Although the long-term impact of these tariffs remains uncertain, the immediate effect has been a heightened emphasis on vertical integration, local cultivation schemes, and innovative sourcing strategies.

Key Segmentation Insights Across Multiple Dimensions

A nuanced understanding of market segmentation is crucial for identifying high-value opportunities and tailoring product development. By Type of Botanical Source, the sector encompasses fungal, marine, and plant origins, with mushrooms and yeasts offering immunomodulatory potentials, corals and seaweed serving as rich sources of unique polysaccharides, and algal, herbal, and moss derivatives providing traditional and novel bioactives. Examining Mode of Administration reveals distinct pathways: oral delivery through capsules, syrups, or tablets remains predominant for systemic therapies, while parenteral innovations-such as injectable and intravenous preparations-address acute conditions, and topical creams, gels, and ointments target dermatological and localized ailments.

Therapeutic Application spans cancer treatment, cardiovascular health, and chronic pain management, where hematological and solid tumor indications, blood pressure regulation and heart defect interventions, and arthritis and neuralgia relief drive specialized formulation demands. Looking at Formula Derivative shows a split between essential oils-applied across aromatherapy and topical uses-and extracts, delivered as aqueous or ethanol concentrates for precise dosing. Patient Demographics reveal differentiated needs across adult, geriatric, and pediatric populations, gender-specific formulations for females and males, and protocols adapted for healthy adults versus immunocompromised individuals. From an End-Use Industry perspective, the nutritional supplement domain includes dietary supplements and functional foods, whereas the pharmaceutical segment covers both over-the-counter remedies and prescription drug channels. Finally, Market Participants range from distributors-operating through retail and wholesale networks-to manufacturers, differentiated by large-scale operations and small-to-medium enterprises. This granular segmentation framework empowers stakeholders to align R&D priorities, marketing strategies, and distribution models with targeted patient cohorts and therapeutic niches.

Key Regional Insights Driving Market Dynamics

The botanical drug market exhibits distinctive regional characteristics that influence regulatory environments, consumer behavior, and supply chain configurations. In the Americas, a robust blend of academic research, venture capital funding, and patient advocacy has accelerated the development of synthetic biology platforms and advanced analytics. Canada’s progressive regulatory stance on plant-derived therapies complements the U.S. focus on innovative clinical trial designs, driving cross-border collaborations that optimize resource utilization.

In Europe, Middle East & Africa, heterogeneous regulatory frameworks coexist with deep-rooted herbal traditions-from Eastern Europe’s long history of phytotherapy to North Africa’s medicinal plant heritage-fostering a rich tapestry of research initiatives. The European Medicines Agency’s botanical monograph system provides standardized quality benchmarks, while emerging markets in the Gulf region invest heavily in biotech infrastructure to bolster indigenous drug development.

Asia-Pacific remains a powerhouse of botanical innovation, leveraging millennia-old knowledge systems in Traditional Chinese, Ayurvedic, and other traditional medicines. China’s massive cultivation capacity and India’s growing clinical research footprint complement Southeast Asia’s biodiversity hotspots, all underpinned by government incentives to commercialize plant-based therapies. This tri-regional perspective underscores the importance of tailored regulatory strategies, localized supply chains, and culturally attuned marketing approaches for global success.

Key Companies Shaping the Botanical Drug Ecosystem

The competitive landscape for botanical drugs is both diverse and rapidly evolving, featuring established pharmaceutical corporations alongside agile biotech startups. Aphios Corporation has pioneered encapsulation technologies for plant-derived cannabinoids, while Botanix Pharmaceuticals Ltd. leverages synthetic biology to produce consistent antimicrobial peptides. CanniMed Therapeutics Inc. and Cardiol Therapeutics Inc. are notable for advancing clinical programs in cardiovascular indications, and CV Sciences, Inc. excels in nutraceutical formulations that integrate hemp extracts.

Ecofibre Limited and EcoGen Laboratories focus on supply chain traceability and sustainable hemp cultivation, whereas Emerald Health Pharmaceuticals and GB Sciences, Inc. have initiated phase II trials for neuroprotective and analgesic botanical compounds. GW Pharmaceuticals plc maintains a leadership position in cannabinoid-based therapies, complemented by HempMeds’ direct-to-consumer wellness offerings. InMed Pharmaceuticals Inc. explores rare cannabinoid biosynthesis, Jazz Pharmaceuticals plc invests in adjunctive botanical pain management, and Lexaria Bioscience Corp. develops enhanced-delivery platforms. MediPharm Labs Corp. and PhytoTech Therapeutics Ltd. have refined extraction and purification processes, while Tetra Bio-Pharma Inc. and Tikun Olam Ltd. pursue oncology and immunology programs. Veritas Pharma Inc. emphasizes quality-by-design manufacturing, and Zynerba Pharmaceuticals, Inc. applies transdermal delivery for cannabinoid therapeutics. Together, these companies illustrate a dynamic ecosystem where scientific rigor, strategic partnerships, and regulatory engagement converge to accelerate botanical drug innovation.

Actionable Recommendations for Industry Leaders

To capitalize on emerging trends and mitigate risks, industry leaders should consider adopting several strategic imperatives. First, invest in state-of-the-art extraction and formulation platforms that enhance bioavailability and allow for precise dose control, thereby differentiating products in a crowded market. Second, pursue vertically integrated supply chains by establishing dedicated cultivation and processing facilities in tariff-advantaged regions or partnering with local growers to secure critical raw materials and reduce cost volatility. Third, engage proactively with regulatory agencies to co-create guidance documents, participate in botanical monograph initiatives, and contribute to clinical trial design standards, ensuring smoother approval pathways.

Fourth, develop data-driven patient segmentation models that leverage real-world evidence from digital health platforms and biomarker studies, enabling personalized therapeutic solutions. Fifth, forge cross-sector alliances with academic institutions, contract research organizations, and technology providers to accelerate R&D timelines and share risk. Finally, prioritize sustainable practices across cultivation, extraction, and packaging-emphasizing eco-certifications and circular economy principles-to meet both regulatory expectations and consumer preferences. By executing these recommendations, organizations can strengthen their competitive positioning and deliver botanical therapies that meet stringent quality, safety, and efficacy benchmarks.

Conclusion: Charting the Future of Botanical Therapeutics

The botanical drug market is poised for transformative growth, driven by scientific innovation, evolving regulatory frameworks, and expanding consumer demand for natural therapeutics. Stakeholders who embrace advanced extraction technologies, cultivate resilient supply chains, and engage collaboratively with regulators will unlock new avenues for product differentiation and market penetration. By integrating robust patient segmentation strategies and forging strategic alliances, companies can accelerate development timelines and optimize resource deployment. As regional dynamics continue to shape global opportunities, organizations that align their commercial and R&D strategies with local market characteristics will secure sustainable growth. Ultimately, the convergence of tradition and technology heralds a new era for botanical drugs-one defined by evidence-based applications that address unmet medical needs.

Market Segmentation & Coverage

This research report categorizes the Botanical Drug Market to forecast the revenues and analyze trends in each of the following sub-segmentations:

  • Fungal Source
    • Mushrooms
    • Yeasts
  • Marine Source
    • Corals
    • Seaweed
  • Plant Source
    • Algal
    • Herbal
    • Moss
  • Oral
    • Capsule
    • Syrup
    • Tablet
  • Parenteral
    • Injection
    • Intravenous
  • Topical
    • Cream
    • Gel
    • Ointment
  • Cancer Treatment
    • Hematological Cancers
    • Solid Tumors
  • Cardiovascular Health
    • Blood Pressure Regulation
    • Heart Defects
  • Chronic Pain Management
    • Arthritis
    • Neuralgia
  • Essential Oils
    • Aromatherapy
    • Topical Applications
  • Extract
    • Aqueous Extract
    • Ethanol Extract
  • Age Group
    • Adult
    • Geriatric
    • Pediatric
  • Gender
    • Female
    • Male
  • Health Status
    • Healthy Adults
    • Immunocompromised
  • Nutraceuticals
    • Dietary Supplements
    • Functional Foods
  • Pharmaceutical
    • Over-the-Counter
    • Prescription Drugs
  • Distributors
    • Retail
    • Wholesale
  • Manufacturers
    • Large-Scale
    • Small-Medium Enterprises

This research report categorizes the Botanical Drug Market to forecast the revenues and analyze trends in each of the following sub-regions:

  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

This research report categorizes the Botanical Drug Market to delves into recent significant developments and analyze trends in each of the following companies:

  • Aphios Corporation
  • Botanix Pharmaceuticals Ltd
  • CanniMed Therapeutics Inc.
  • Cardiol Therapeutics Inc.
  • CV Sciences, Inc.
  • Ecofibre Limited
  • EcoGen Laboratories
  • Emerald Health Pharmaceuticals
  • GB Sciences, Inc.
  • GW Pharmaceuticals plc
  • HempMeds
  • InMed Pharmaceuticals Inc.
  • Jazz Pharmaceuticals plc
  • Lexaria Bioscience Corp.
  • MediPharm Labs Corp.
  • PhytoTech Therapeutics Ltd.
  • Tetra Bio-Pharma Inc.
  • Tikun Olam Ltd.
  • Veritas Pharma Inc.
  • Zynerba Pharmaceuticals, Inc.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Botanical Drug Market, by Type of Botanical Source
8.1. Introduction
8.2. Fungal Source
8.2.1. Mushrooms
8.2.2. Yeasts
8.3. Marine Source
8.3.1. Corals
8.3.2. Seaweed
8.4. Plant Source
8.4.1. Algal
8.4.2. Herbal
8.4.3. Moss
9. Botanical Drug Market, by Mode of Administration
9.1. Introduction
9.2. Oral
9.2.1. Capsule
9.2.2. Syrup
9.2.3. Tablet
9.3. Parenteral
9.3.1. Injection
9.3.2. Intravenous
9.4. Topical
9.4.1. Cream
9.4.2. Gel
9.4.3. Ointment
10. Botanical Drug Market, by Therapeutic Application
10.1. Introduction
10.2. Cancer Treatment
10.2.1. Hematological Cancers
10.2.2. Solid Tumors
10.3. Cardiovascular Health
10.3.1. Blood Pressure Regulation
10.3.2. Heart Defects
10.4. Chronic Pain Management
10.4.1. Arthritis
10.4.2. Neuralgia
11. Botanical Drug Market, by Formula Derivative
11.1. Introduction
11.2. Essential Oils
11.2.1. Aromatherapy
11.2.2. Topical Applications
11.3. Extract
11.3.1. Aqueous Extract
11.3.2. Ethanol Extract
12. Botanical Drug Market, by Patient Demographics
12.1. Introduction
12.2. Age Group
12.2.1. Adult
12.2.2. Geriatric
12.2.3. Pediatric
12.3. Gender
12.3.1. Female
12.3.2. Male
12.4. Health Status
12.4.1. Healthy Adults
12.4.2. Immunocompromised
13. Botanical Drug Market, by End-Use Industry
13.1. Introduction
13.2. Nutraceuticals
13.2.1. Dietary Supplements
13.2.2. Functional Foods
13.3. Pharmaceutical
13.3.1. Over-the-Counter
13.3.2. Prescription Drugs
14. Botanical Drug Market, by Market Participants Type
14.1. Introduction
14.2. Distributors
14.2.1. Retail
14.2.2. Wholesale
14.3. Manufacturers
14.3.1. Large-Scale
14.3.2. Small-Medium Enterprises
15. Americas Botanical Drug Market
15.1. Introduction
15.2. Argentina
15.3. Brazil
15.4. Canada
15.5. Mexico
15.6. United States
16. Asia-Pacific Botanical Drug Market
16.1. Introduction
16.2. Australia
16.3. China
16.4. India
16.5. Indonesia
16.6. Japan
16.7. Malaysia
16.8. Philippines
16.9. Singapore
16.10. South Korea
16.11. Taiwan
16.12. Thailand
16.13. Vietnam
17. Europe, Middle East & Africa Botanical Drug Market
17.1. Introduction
17.2. Denmark
17.3. Egypt
17.4. Finland
17.5. France
17.6. Germany
17.7. Israel
17.8. Italy
17.9. Netherlands
17.10. Nigeria
17.11. Norway
17.12. Poland
17.13. Qatar
17.14. Russia
17.15. Saudi Arabia
17.16. South Africa
17.17. Spain
17.18. Sweden
17.19. Switzerland
17.20. Turkey
17.21. United Arab Emirates
17.22. United Kingdom
18. Competitive Landscape
18.1. Market Share Analysis, 2024
18.2. FPNV Positioning Matrix, 2024
18.3. Competitive Analysis
18.3.1. Aphios Corporation
18.3.2. Botanix Pharmaceuticals Ltd
18.3.3. CanniMed Therapeutics Inc.
18.3.4. Cardiol Therapeutics Inc.
18.3.5. CV Sciences, Inc.
18.3.6. Ecofibre Limited
18.3.7. EcoGen Laboratories
18.3.8. Emerald Health Pharmaceuticals
18.3.9. GB Sciences, Inc.
18.3.10. GW Pharmaceuticals plc
18.3.11. HempMeds
18.3.12. InMed Pharmaceuticals Inc.
18.3.13. Jazz Pharmaceuticals plc
18.3.14. Lexaria Bioscience Corp.
18.3.15. MediPharm Labs Corp.
18.3.16. PhytoTech Therapeutics Ltd.
18.3.17. Tetra Bio-Pharma Inc.
18.3.18. Tikun Olam Ltd.
18.3.19. Veritas Pharma Inc.
18.3.20. Zynerba Pharmaceuticals, Inc.
19. ResearchAI
20. ResearchStatistics
21. ResearchContacts
22. ResearchArticles
23. Appendix
List of Figures
FIGURE 1. BOTANICAL DRUG MARKET MULTI-CURRENCY
FIGURE 2. BOTANICAL DRUG MARKET MULTI-LANGUAGE
FIGURE 3. BOTANICAL DRUG MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL BOTANICAL DRUG MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL BOTANICAL DRUG MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL BOTANICAL DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL BOTANICAL DRUG MARKET SIZE, BY TYPE OF BOTANICAL SOURCE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL BOTANICAL DRUG MARKET SIZE, BY TYPE OF BOTANICAL SOURCE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL BOTANICAL DRUG MARKET SIZE, BY MODE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL BOTANICAL DRUG MARKET SIZE, BY MODE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL BOTANICAL DRUG MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL BOTANICAL DRUG MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL BOTANICAL DRUG MARKET SIZE, BY FORMULA DERIVATIVE, 2024 VS 2030 (%)
FIGURE 14. GLOBAL BOTANICAL DRUG MARKET SIZE, BY FORMULA DERIVATIVE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL BOTANICAL DRUG MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2024 VS 2030 (%)
FIGURE 16. GLOBAL BOTANICAL DRUG MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL BOTANICAL DRUG MARKET SIZE, BY END-USE INDUSTRY, 2024 VS 2030 (%)
FIGURE 18. GLOBAL BOTANICAL DRUG MARKET SIZE, BY END-USE INDUSTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. GLOBAL BOTANICAL DRUG MARKET SIZE, BY MARKET PARTICIPANTS TYPE, 2024 VS 2030 (%)
FIGURE 20. GLOBAL BOTANICAL DRUG MARKET SIZE, BY MARKET PARTICIPANTS TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. AMERICAS BOTANICAL DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. AMERICAS BOTANICAL DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. UNITED STATES BOTANICAL DRUG MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 24. UNITED STATES BOTANICAL DRUG MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ASIA-PACIFIC BOTANICAL DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. ASIA-PACIFIC BOTANICAL DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. EUROPE, MIDDLE EAST & AFRICA BOTANICAL DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 28. EUROPE, MIDDLE EAST & AFRICA BOTANICAL DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 29. BOTANICAL DRUG MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 30. BOTANICAL DRUG MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. BOTANICAL DRUG MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL BOTANICAL DRUG MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL BOTANICAL DRUG MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL BOTANICAL DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL BOTANICAL DRUG MARKET SIZE, BY TYPE OF BOTANICAL SOURCE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL BOTANICAL DRUG MARKET SIZE, BY FUNGAL SOURCE, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL BOTANICAL DRUG MARKET SIZE, BY MUSHROOMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL BOTANICAL DRUG MARKET SIZE, BY YEASTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL BOTANICAL DRUG MARKET SIZE, BY FUNGAL SOURCE, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL BOTANICAL DRUG MARKET SIZE, BY MARINE SOURCE, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL BOTANICAL DRUG MARKET SIZE, BY CORALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL BOTANICAL DRUG MARKET SIZE, BY SEAWEED, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL BOTANICAL DRUG MARKET SIZE, BY MARINE SOURCE, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL BOTANICAL DRUG MARKET SIZE, BY PLANT SOURCE, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL BOTANICAL DRUG MARKET SIZE, BY ALGAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL BOTANICAL DRUG MARKET SIZE, BY HERBAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL BOTANICAL DRUG MARKET SIZE, BY MOSS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL BOTANICAL DRUG MARKET SIZE, BY PLANT SOURCE, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL BOTANICAL DRUG MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL BOTANICAL DRUG MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL BOTANICAL DRUG MARKET SIZE, BY CAPSULE, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL BOTANICAL DRUG MARKET SIZE, BY SYRUP, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL BOTANICAL DRUG MARKET SIZE, BY TABLET, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL BOTANICAL DRUG MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL BOTANICAL DRUG MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL BOTANICAL DRUG MARKET SIZE, BY INJECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL BOTANICAL DRUG MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL BOTANICAL DRUG MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL BOTANICAL DRUG MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL BOTANICAL DRUG MARKET SIZE, BY CREAM, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL BOTANICAL DRUG MARKET SIZE, BY GEL, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL BOTANICAL DRUG MARKET SIZE, BY OINTMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL BOTANICAL DRUG MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL BOTANICAL DRUG MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL BOTANICAL DRUG MARKET SIZE, BY CANCER TREATMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL BOTANICAL DRUG MARKET SIZE, BY HEMATOLOGICAL CANCERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL BOTANICAL DRUG MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL BOTANICAL DRUG MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL BOTANICAL DRUG MARKET SIZE, BY CARDIOVASCULAR HEALTH, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL BOTANICAL DRUG MARKET SIZE, BY BLOOD PRESSURE REGULATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL BOTANICAL DRUG MARKET SIZE, BY HEART DEFECTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL BOTANICAL DRUG MARKET SIZE, BY CARDIOVASCULAR HEALTH, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL BOTANICAL DRUG MARKET SIZE, BY CHRONIC PAIN MANAGEMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL BOTANICAL DRUG MARKET SIZE, BY ARTHRITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL BOTANICAL DRUG MARKET SIZE, BY NEURALGIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL BOTANICAL DRUG MARKET SIZE, BY CHRONIC PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL BOTANICAL DRUG MARKET SIZE, BY FORMULA DERIVATIVE, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL BOTANICAL DRUG MARKET SIZE, BY ESSENTIAL OILS, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL BOTANICAL DRUG MARKET SIZE, BY AROMATHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL BOTANICAL DRUG MARKET SIZE, BY TOPICAL APPLICATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL BOTANICAL DRUG MARKET SIZE, BY ESSENTIAL OILS, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL BOTANICAL DRUG MARKET SIZE, BY EXTRACT, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL BOTANICAL DRUG MARKET SIZE, BY AQUEOUS EXTRACT, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL BOTANICAL DRUG MARKET SIZE, BY ETHANOL EXTRACT, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL BOTANICAL DRUG MARKET SIZE, BY EXTRACT, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL BOTANICAL DRUG MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL BOTANICAL DRUG MARKET SIZE, BY AGE GROUP, BY REGION, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL BOTANICAL DRUG MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL BOTANICAL DRUG MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL BOTANICAL DRUG MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 62. GLOBAL BOTANICAL DRUG MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 63. GLOBAL BOTANICAL DRUG MARKET SIZE, BY GENDER, BY REGION, 2018-2030 (USD MILLION)
TABLE 64. GLOBAL BOTANICAL DRUG MARKET SIZE, BY FEMALE, BY REGION, 2018-2030 (USD MILLION)
TABLE 65. GLOBAL BOTANICAL DRUG MARKET SIZE, BY MALE, BY REGION, 2018-2030 (USD MILLION)
TABLE 66. GLOBAL BOTANICAL DRUG MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 67. GLOBAL BOTANICAL DRUG MARKET SIZE, BY HEALTH STATUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 68. GLOBAL BOTANICAL DRUG MARKET SIZE, BY HEALTHY ADULTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 69. GLOBAL BOTANICAL DRUG MARKET SIZE, BY IMMUNOCOMPROMISED, BY REGION, 2018-2030 (USD MILLION)
TABLE 70. GLOBAL BOTANICAL DRUG MARKET SIZE, BY HEALTH STATUS, 2018-2030 (USD MILLION)
TABLE 71. GLOBAL BOTANICAL DRUG MARKET SIZE, BY END-USE INDUSTRY, 2018-2030 (USD MILLION)
TABLE 72. GLOBAL BOTANICAL DRUG MARKET SIZE, BY NUTRACEUTICALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 73. GLOBAL BOTANICAL DRUG MARKET SIZE, BY DIETARY SUPPLEMENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 74. GLOBAL BOTANICAL DRUG MARKET SIZE, BY FUNCTIONAL FOODS, BY REGION, 2018-2030 (USD MILLION)
TABLE 75. GLOBAL BOTANICAL DRUG MARKET SIZE, BY NUTRACEUTICALS, 2018-2030 (USD MILLION)
TABLE 76. GLOBAL BOTANICAL DRUG MARKET SIZE, BY PHARMACEUTICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 77. GLOBAL BOTANICAL DRUG MARKET SIZE, BY OVER-THE-COUNTER, BY REGION, 2018-2030 (USD MILLION)
TABLE 78. GLOBAL BOTANICAL DRUG MARKET SIZE, BY PRESCRIPTION DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 79. GLOBAL BOTANICAL DRUG MARKET SIZE, BY PHARMACEUTICAL, 2018-2030 (USD MILLION)
TABLE 80. GLOBAL BOTANICAL DRUG MARKET SIZE, BY MARKET PARTICIPANTS TYPE, 2018-2030 (USD MILLION)
TABLE 81. GLOBAL BOTANICAL DRUG MARKET SIZE, BY DISTRIBUTORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 82. GLOBAL BOTANICAL DRUG MARKET SIZE, BY RETAIL, BY REGION, 2018-2030 (USD MILLION)
TABLE 83. GLOBAL BOTANICAL DRUG MARKET SIZE, BY WHOLESALE, BY REGION, 2018-2030 (USD MILLION)
TABLE 84. GLOBAL BOTANICAL DRUG MARKET SIZE, BY DISTRIBUTORS, 2018-2030 (USD MILLION)
TABLE 85. GLOBAL BOTANICAL DRUG MARKET SIZE, BY MANUFACTURERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 86. GLOBAL BOTANICAL DRUG MARKET SIZE, BY LARGE-SCALE, BY REGION, 2018-2030 (USD MILLION)
TABLE 87. GLOBAL BOTANICAL DRUG MARKET SIZE, BY SMALL-MEDIUM ENTERPRISES, BY REGION, 2018-2030 (USD MILLION)
TABLE 88. GLOBAL BOTANICAL DRUG MARKET SIZE, BY MANUFACTURERS, 2018-2030 (USD MILLION)
TABLE 89. AMERICAS BOTANICAL DRUG MARKET SIZE, BY TYPE OF BOTANICAL SOURCE, 2018-2030 (USD MILLION)
TABLE 90. AMERICAS BOTANICAL DRUG MARKET SIZE, BY FUNGAL SOURCE, 2018-2030 (USD MILLION)
TABLE 91. AMERICAS BOTANICAL DRUG MARKET SIZE, BY MARINE SOURCE, 2018-2030 (USD MILLION)
TABLE 92. AMERICAS BOTANICAL DRUG MARKET SIZE, BY PLANT SOURCE, 2018-2030 (USD MILLION)
TABLE 93. AMERICAS BOTANICAL DRUG MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 94. AMERICAS BOTANICAL DRUG MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 95. AMERICAS BOTANICAL DRUG MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 96. AMERICAS BOTANICAL DRUG MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 97. AMERICAS BOTANICAL DRUG MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 98. AMERICAS BOTANICAL DRUG MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
TABLE 99. AMERICAS BOTANICAL DRUG MARKET SIZE, BY CARDIOVASCULAR HEALTH, 2018-2030 (USD MILLION)
TABLE 100. AMERICAS BOTANICAL DRUG MARKET SIZE, BY CHRONIC PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 101. AMERICAS BOTANICAL DRUG MARKET SIZE, BY FORMULA DERIVATIVE, 2018-2030 (USD MILLION)
TABLE 102. AMERICAS BOTANICAL DRUG MARKET SIZE, BY ESSENTIAL OILS, 2018-2030 (USD MILLION)
TABLE 103. AMERICAS BOTANICAL DRUG MARKET SIZE, BY EXTRACT, 2018-2030 (USD MILLION)
TABLE 104. AMERICAS BOTANICAL DRUG MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 105. AMERICAS BOTANICAL DRUG MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 106. AMERICAS BOTANICAL DRUG MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 107. AMERICAS BOTANICAL DRUG MARKET SIZE, BY HEALTH STATUS, 2018-2030 (USD MILLION)
TABLE 108. AMERICAS BOTANICAL DRUG MARKET SIZE, BY END-USE INDUSTRY, 2018-2030 (USD MILLION)
TABLE 109. AMERICAS BOTANICAL DRUG MARKET SIZE, BY NUTRACEUTICALS, 2018-2030 (USD MILLION)
TABLE 110. AMERICAS BOTANICAL DRUG MARKET SIZE, BY PHARMACEUTICAL, 2018-2030 (USD MILLION)
TABLE 111. AMERICAS BOTANICAL DRUG MARKET SIZE, BY MARKET PARTICIPANTS TYPE, 2018-2030 (USD MILLION)
TABLE 112. AMERICAS BOTANICAL DRUG MARKET SIZE, BY DISTRIBUTORS, 2018-2030 (USD MILLION)
TABLE 113. AMERICAS BOTANICAL DRUG MARKET SIZE, BY MANUFACTURERS, 2018-2030 (USD MILLION)
TABLE 114. AMERICAS BOTANICAL DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 115. ARGENTINA BOTANICAL DRUG MARKET SIZE, BY TYPE OF BOTANICAL SOURCE, 2018-2030 (USD MILLION)
TABLE 116. ARGENTINA BOTANICAL DRUG MARKET SIZE, BY FUNGAL SOURCE, 2018-2030 (USD MILLION)
TABLE 117. ARGENTINA BOTANICAL DRUG MARKET SIZE, BY MARINE SOURCE, 2018-2030 (USD MILLION)
TABLE 118. ARGENTINA BOTANICAL DRUG MARKET SIZE, BY PLANT SOURCE, 2018-2030 (USD MILLION)
TABLE 119. ARGENTINA BOTANICAL DRUG MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 120. ARGENTINA BOTANICAL DRUG MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 121. ARGENTINA BOTANICAL DRUG MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 122. ARGENTINA BOTANICAL DRUG MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 123. ARGENTINA BOTANICAL DRUG MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 124. ARGENTINA BOTANICAL DRUG MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
TABLE 125. ARGENTINA BOTANICAL DRUG MARKET SIZE, BY CARDIOVASCULAR HEALTH, 2018-2030 (USD MILLION)
TABLE 126. ARGENTINA BOTANICAL DRUG MARKET SIZE, BY CHRONIC PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 127. ARGENTINA BOTANICAL DRUG MARKET SIZE, BY FORMULA DERIVATIVE, 2018-2030 (USD MILLION)
TABLE 128. ARGENTINA BOTANICAL DRUG MARKET SIZE, BY ESSENTIAL OILS, 2018-2030 (USD MILLION)
TABLE 129. ARGENTINA BOTANICAL DRUG MARKET SIZE, BY EXTRACT, 2018-2030 (USD MILLION)
TABLE 130. ARGENTINA BOTANICAL DRUG MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 131. ARGENTINA BOTANICAL DRUG MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 132. ARGENTINA BOTANICAL DRUG MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 133. ARGENTINA BOTANICAL DRUG MARKET SIZE, BY HEALTH STATUS, 2018-2030 (USD MILLION)
TABLE 134. ARGENTINA BOTANICAL DRUG MARKET SIZE, BY END-USE INDUSTRY, 2018-2030 (USD MILLION)
TABLE 135. ARGENTINA BOTANICAL DRUG MARKET SIZE, BY NUTRACEUTICALS, 2018-2030 (USD MILLION)
TABLE 136. ARGENTINA BOTANICAL DRUG MARKET SIZE, BY PHARMACEUTICAL, 2018-2030 (USD MILLION)
TABLE 137. ARGENTINA BOTANICAL DRUG MARKET SIZE, BY MARKET PARTICIPANTS TYPE, 2018-2030 (USD MILLION)
TABLE 138. ARGENTINA BOTANICAL DRUG MARKET SIZE, BY DISTRIBUTORS, 2018-2030 (USD MILLION)
TABLE 139. ARGENTINA BOTANICAL DRUG MARKET SIZE, BY MANUFACTURERS, 2018-2030 (USD MILLION)
TABLE 140. BRAZIL BOTANICAL DRUG MARKET SIZE, BY TYPE OF BOTANICAL SOURCE, 2018-2030 (USD MILLION)
TABLE 141. BRAZIL BOTANICAL DRUG MARKET SIZE, BY FUNGAL SOURCE, 2018-2030 (USD MILLION)
TABLE 142. BRAZIL BOTANICAL DRUG MARKET SIZE, BY MARINE SOURCE, 2018-2030 (USD MILLION)
TABLE 143. BRAZIL BOTANICAL DRUG MARKET SIZE, BY PLANT SOURCE, 2018-2030 (USD MILLION)
TABLE 144. BRAZIL BOTANICAL DRUG MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 145. BRAZIL BOTANICAL DRUG MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 146. BRAZIL BOTANICAL DRUG MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 147. BRAZIL BOTANICAL DRUG MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 148. BRAZIL BOTANICAL DRUG MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 149. BRAZIL BOTANICAL DRUG MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
TABLE 150. BRAZIL BOTANICAL DRUG MARKET SIZE, BY CARDIOVASCULAR HEALTH, 2018-2030 (USD MILLION)
TABLE 151. BRAZIL BOTANICAL DRUG MARKET SIZE, BY CHRONIC PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 152. BRAZIL BOTANICAL DRUG MARKET SIZE, BY FORMULA DERIVATIVE, 2018-2030 (USD MILLION)
TABLE 153. BRAZIL BOTANICAL DRUG MARKET SIZE, BY ESSENTIAL OILS, 2018-2030 (USD MILLION)
TABLE 154. BRAZIL BOTANICAL DRUG MARKET SIZE, BY EXTRACT, 2018-2030 (USD MILLION)
TABLE 155. BRAZIL BOTANICAL DRUG MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 156. BRAZIL BOTANICAL DRUG MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 157. BRAZIL BOTANICAL DRUG MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 158. BRAZIL BOTANICAL DRUG MARKET SIZE, BY HEALTH STATUS, 2018-2030 (USD MILLION)
TABLE 159. BRAZIL BOTANICAL DRUG MARKET SIZE, BY END-USE INDUSTRY, 2018-2030 (USD MILLION)
TABLE 160. BRAZIL BOTANICAL DRUG MARKET SIZE, BY NUTRACEUTICALS, 2018-2030 (USD MILLION)
TABLE 161. BRAZIL BOTANICAL DRUG MARKET SIZE, BY PHARMACEUTICAL, 2018-2030 (USD MILLION)
TABLE 162. BRAZIL BOTANICAL DRUG MARKET SIZE, BY MARKET PARTICIPANTS TYPE, 2018-2030 (USD MILLION)
TABLE 163. BRAZIL BOTANICAL DRUG MARKET SIZE, BY DISTRIBUTORS, 2018-2030 (USD MILLION)
TABLE 164. BRAZIL BOTANICAL DRUG MARKET SIZE, BY MANUFACTURERS, 2018-2030 (USD MILLION)
TABLE 165. CANADA BOTANICAL DRUG MARKET SIZE, BY TYPE OF BOTANICAL SOURCE, 2018-2030 (USD MILLION)
TABLE 166. CANADA BOTANICAL DRUG MARKET SIZE, BY FUNGAL SOURCE, 2018-2030 (USD MILLION)
TABLE 167. CANADA BOTANICAL DRUG MARKET SIZE, BY MARINE SOURCE, 2018-2030 (USD MILLION)
TABLE 168. CANADA BOTANICAL DRUG MARKET SIZE, BY PLANT SOURCE, 2018-2030 (USD MILLION)
TABLE 169. CANADA BOTANICAL DRUG MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 170. CANADA BOTANICAL DRUG MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 171. CANADA BOTANICAL DRUG MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 172. CANADA BOTANICAL DRUG MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 173. CANADA BOTANICAL DRUG MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 174. CANADA BOTANICAL DRUG MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
TABLE 175. CANADA BOTANICAL DRUG MARKET SIZE, BY CARDIOVASCULAR HEALTH, 2018-2030 (USD MILLION)
TABLE 176. CANADA BOTANICAL DRUG MARKET SIZE, BY CHRONIC PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 177. CANADA BOTANICAL DRUG MARKET SIZE, BY FORMULA DERIVATIVE, 2018-2030 (USD MILLION)
TABLE 178. CANADA BOTANICAL DRUG MARKET SIZE, BY ESSENTIAL OILS, 2018-2030 (USD MILLION)
TABLE 179. CANADA BOTANICAL DRUG MARKET SIZE, BY EXTRACT, 2018-2030 (USD MILLION)
TABLE 180. CANADA BOTANICAL DRUG MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 181. CANADA BOTANICAL DRUG MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 182. CANADA BOTANICAL DRUG MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 183. CANADA BOTANICAL DRUG MARKET SIZE, BY HEALTH STATUS, 2018-2030 (USD MILLION)
TABLE 184. CANADA BOTANICAL DRUG MARKET SIZE, BY END-USE INDUSTRY, 2018-2030 (USD MILLION)
TABLE 185. CANADA BOTANICAL DRUG MARKET SIZE, BY NUTRACEUTICALS, 2018-2030 (USD MILLION)
TABLE 186. CANADA BOTANICAL DRUG MARKET SIZE, BY PHARMACEUTICAL, 2018-2030 (USD MILLION)
TABLE 187. CANADA BOTANICAL DRUG MARKET SIZE, BY MARKET PARTICIPANTS TYPE, 2018-2030 (USD MILLION)
TABLE 188. CANADA BOTANICAL DRUG MARKET SIZE, BY DISTRIBUTORS, 2018-2030 (USD MILLION)
TABLE 189. CANADA BOTANICAL DRUG MARKET SIZE, BY MANUFACTURERS, 2018-2030 (USD MILLION)
TABLE 190. MEXICO BOTANICAL DRUG MARKET SIZE, BY TYPE OF BOTANICAL SOURCE, 2018-2030 (USD MILLION)
TABLE 191. MEXICO BOTANICAL DRUG MARKET SIZE, BY FUNGAL SOURCE, 2018-2030 (USD MILLION)
TABLE 192. MEXICO BOTANICAL DRUG MARKET SIZE, BY MARINE SOURCE, 2018-2030 (USD MILLION)
TABLE 193. MEXICO BOTANICAL DRUG MARKET SIZE, BY PLANT SOURCE, 2018-2030 (USD MILLION)
TABLE 194. MEXICO BOTANICAL DRUG MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 195. MEXICO BOTANICAL DRUG MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 196. MEXICO BOTANICAL DRUG MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 197. MEXICO BOTANICAL DRUG MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 198. MEXICO BOTANICAL DRUG MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 199. MEXICO BOTANICAL DRUG MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
TABLE 200. MEXICO BOTANICAL DRUG MARKET SIZE, BY CARDIOVASCULAR HEALTH, 2018-2030 (USD MILLION)
TABLE 201. MEXICO BOTANICAL DRUG MARKET SIZE, BY CHRONIC PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 202. MEXICO BOTANICAL DRUG MARKET SIZE, BY FORMULA DERIVATIVE, 2018-2030 (USD MILLION)
TABLE 203. MEXICO BOTANICAL DRUG MARKET SIZE, BY ESSENTIAL OILS, 2018-2030 (USD MILLION)
TABLE 204. MEXICO BOTANICAL DRUG MARKET SIZE, BY EXTRACT, 2018-2030 (USD MILLION)
TABLE 205. MEXICO BOTANICAL DRUG MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 206. MEXICO BOTANICAL DRUG MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 207. MEXICO BOTANICAL DRUG MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 208. MEXICO BOTANICAL DRUG MARKET SIZE, BY HEALTH STATUS, 2018-2030 (USD MILLION)
TABLE 209. MEXICO BOTANICAL DRUG MARKET SIZE, BY END-USE INDUSTRY, 2018-2030 (USD MILLION)
TABLE 210. MEXICO BOTANICAL DRUG MARKET SIZE, BY NUTRACEUTICALS, 2018-2030 (USD MILLION)
TABLE 211. MEXICO BOTANICAL DRUG MARKET SIZE, BY PHARMACEUTICAL, 2018-2030 (USD MILLION)
TABLE 212. MEXICO BOTANICAL DRUG MARKET SIZE, BY MARKET PARTICIPANTS TYPE, 2018-2030 (USD MILLION)
TABLE 213. MEXICO BOTANICAL DRUG MARKET SIZE, BY DISTRIBUTORS, 2018-2030 (USD MILLION)
TABLE 214. MEXICO BOTANICAL DRUG MARKET SIZE, BY MANUFACTURERS, 2018-2030 (USD MILLION)
TABLE 215. UNITED STATES BOTANICAL DRUG MARKET SIZE, BY TYPE OF BOTANICAL SOURCE, 2018-2030 (USD MILLION)
TABLE 216. UNITED STATES BOTANICAL DRUG MARKET SIZE, BY FUNGAL SOURCE, 2018-2030 (USD MILLION)
TABLE 217. UNITED STATES BOTANICAL DRUG MARKET SIZE, BY MARINE SOURCE, 2018-2030 (USD MILLION)
TABLE 218. UNITED STATES BOTANICAL DRUG MARKET SIZE, BY PLANT SOURCE, 2018-2030 (USD MILLION)
TABLE 219. UNITED STATES BOTANICAL DRUG MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 220. UNITED STATES BOTANICAL DRUG MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 221. UNITED STATES BOTANICAL DRUG MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 222. UNITED STATES BOTANICAL DRUG MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 223. UNITED STATES BOTANICAL DRUG MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 224. UNITED STATES BOTANICAL DRUG MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
TABLE 225. UNITED STATES BOTANICAL DRUG MARKET SIZE, BY CARDIOVASCULAR HEALTH, 2018-2030 (USD MILLION)
TABLE 226. UNITED STATES BOTANICAL DRUG MARKET SIZE, BY CHRONIC PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 227. UNITED STATES BOTANICAL DRUG MARKET SIZE, BY FORMULA DERIVATIVE, 2018-2030 (USD MILLION)
TABLE 228. UNITED STATES BOTANICAL DRUG MARKET SIZE, BY ESSENTIAL OILS, 2018-2030 (USD MILLION)
TABLE 229. UNITED STATES BOTANICAL DRUG MARKET SIZE, BY EXTRACT, 2018-2030 (USD MILLION)
TABLE 230. UNITED STATES BOTANICAL DRUG MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 231. UNITED STATES BOTANICAL DRUG MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 232. UNITED STATES BOTANICAL DRUG MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 233. UNITED STATES BOTANICAL DRUG MARKET SIZE, BY HEALTH STATUS, 2018-2030 (USD MILLION)
TABLE 234. UNITED STATES BOTANICAL DRUG MARKET SIZE, BY END-USE INDUSTRY, 2018-2030 (USD MILLION)
TABLE 235. UNITED STATES BOTANICAL DRUG MARKET SIZE, BY NUTRACEUTICALS, 2018-2030 (USD MILLION)
TABLE 236. UNITED STATES BOTANICAL DRUG MARKET SIZE, BY PHARMACEUTICAL, 2018-2030 (USD MILLION)
TABLE 237. UNITED STATES BOTANICAL DRUG MARKET SIZE, BY MARKET PARTICIPANTS TYPE, 2018-2030 (USD MILLION)
TABLE 238. UNITED STATES BOTANICAL DRUG MARKET SIZE, BY DISTRIBUTORS, 2018-2030 (USD MILLION)
TABLE 239. UNITED STATES BOTANICAL DRUG MARKET SIZE, BY MANUFACTURERS, 2018-2030 (USD MILLION)
TABLE 240. UNITED STATES BOTANICAL DRUG MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 241. ASIA-PACIFIC BOTANICAL DRUG MARKET SIZE, BY TYPE OF BOTANICAL SOURCE, 2018-2030 (USD MILLION)
TABLE 242. ASIA-PACIFIC BOTANICAL DRUG MARKET SIZE, BY FUNGAL SOURCE, 2018-2030 (USD MILLION)
TABLE 243. ASIA-PACIFIC BOTANICAL DRUG MARKET SIZE, BY MARINE SOURCE, 2018-2030 (USD MILLION)
TABLE 244. ASIA-PACIFIC BOTANICAL DRUG MARKET SIZE, BY PLANT SOURCE, 2018-2030 (USD MILLION)
TABLE 245. ASIA-PACIFIC BOTANICAL DRUG MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 246. ASIA-PACIFIC BOTANICAL DRUG MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 247. ASIA-PACIFIC BOTANICAL DRUG MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 248. ASIA-PACIFIC BOTANICAL DRUG MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 249. ASIA-PACIFIC BOTANICAL DRUG MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 250. ASIA-PACIFIC BOTANICAL DRUG MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
TABLE 251. ASIA-PACIFIC BOTANICAL DRUG MARKET SIZE, BY CARDIOVASCULAR HEALTH, 2018-2030 (USD MILLION)
TABLE 252. ASIA-PACIFIC BOTANICAL DRUG MARKET SIZE, BY CHRONIC PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 253. ASIA-PACIFIC BOTANICAL DRUG MARKET SIZE, BY FORMULA DERIVATIVE, 2018-2030 (USD MILLION)
TABLE 254. ASIA-PACIFIC BOTANICAL DRUG MARKET SIZE, BY ESSENTIAL OILS, 2018-2030 (USD MILLION)
TABLE 255. ASIA-PACIFIC BOTANICAL DRUG MARKET SIZE, BY EXTRACT, 2018-2030 (USD MILLION)
TABLE 256. ASIA-PACIFIC BOTANICAL DRUG MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 257. ASIA-PACIFIC BOTANICAL DRUG MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 258. ASIA-PACIFIC BOTANICAL DRUG MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 259. ASIA-PACIFIC BOTANICAL DRUG MARKET SIZE, BY HEALTH STATUS, 2018-2030 (USD MILLION)
TABLE 260. ASIA-PACIFIC BOTANICAL DRUG MARKET SIZE, BY END-USE INDUSTRY, 2018-2030 (USD MILLION)
TABLE 261. ASIA-PACIFIC BOTANICAL DRUG MARKET SIZE, BY NUTRACEUTICALS, 2018-2030 (USD MILLION)
TABLE 262. ASIA-PACIFIC BOTANICAL DRUG MARKET SIZE, BY PHARMACEUTICAL, 2018-2030 (USD MILLION)
TABLE 263. ASIA-PACIFIC BOTANICAL DRUG MARKET SIZE, BY MARKET PARTICIPANTS TYPE, 2018-2030 (USD MILLION)
TABLE 264. ASIA-PACIFIC BOTANICAL DRUG MARKET SIZE, BY DISTRIBUTORS, 2018-2030 (USD MILLION)
TABLE 265. ASIA-PACIFIC BOTANICAL DRUG MARKET SIZE, BY MANUFACTURERS, 2018-2030 (USD MILLION)
TABLE 266. ASIA-PACIFIC BOTANICAL DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 267. AUSTRALIA BOTANICAL DRUG MARKET SIZE, BY TYPE OF BOTANICAL SOURCE, 2018-2030 (USD MILLION)
TABLE 268. AUSTRALIA BOTANICAL DRUG MARKET SIZE, BY FUNGAL SOURCE, 2018-2030 (USD MILLION)
TABLE 269. AUSTRALIA BOTANICAL DRUG MARKET SIZE, BY MARINE SOURCE, 2018-2030 (USD MILLION)
TABLE 270. AUSTRALIA BOTANICAL DRUG MARKET SIZE, BY PLANT SOURCE, 2018-2030 (USD MILLION)
TABLE 271. AUSTRALIA BOTANICAL DRUG MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 272. AUSTRALIA BOTANICAL DRUG MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 273. AUSTRALIA BOTANICAL DRUG MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 274. AUSTRALIA BOTANICAL DRUG MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 275. AUSTRALIA BOTANICAL DRUG MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 276. AUSTRALIA BOTANICAL DRUG MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
TABLE 277. AUSTRALIA BOTANICAL DRUG MARKET SIZE, BY CARDIOVASCULAR HEALTH, 2018-2030 (USD MILLION)
TABLE 278. AUSTRALIA BOTANICAL DRUG MARKET SIZE, BY CHRONIC PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 279. AUSTRALIA BOTANICAL DRUG MARKET SIZE, BY FORMULA DERIVATIVE, 2018-2030 (USD MILLION)
TABLE 280. AUSTRALIA BOTANICAL DRUG MARKET SIZE, BY ESSENTIAL OILS, 2018-2030 (USD MILLION)
TABLE 281. AUSTRALIA BOTANICAL DRUG MARKET SIZE, BY EXTRACT, 2018-2030 (USD MILLION)
TABLE 282. AUSTRALIA BOTANICAL DRUG MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 283. AUSTRALIA BOTANICAL DRUG MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 284. AUSTRALIA BOTANICAL DRUG MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 285. AUSTRALIA BOTANICAL DRUG MARKET SIZE, BY HEALTH STATUS, 2018-2030 (USD MILLION)
TABLE 286. AUSTRALIA BOTANICAL DRUG MARKET SIZE, BY END-USE INDUSTRY, 2018-2030 (USD MILLION)
TABLE 287. AUSTRALIA BOTANICAL DRUG MARKET SIZE, BY NUTRACEUTICALS, 2018-2030 (USD MILLION)
TABLE 288. AUSTRALIA BOTANICAL DRUG MARKET SIZE, BY PHARMACEUTICAL, 2018-2030 (USD MILLION)
TABLE 289. AUSTRALIA BOTANICAL DRUG MARKET SIZE, BY MARKET PARTICIPANTS TYPE, 2018-2030 (USD MILLION)
TABLE 290. AUSTRALIA BOTANICAL DRUG MARKET SIZE, BY DISTRIBUTORS, 2018-2030 (USD MILLION)
TABLE 291. AUSTRALIA BOTANICAL DRUG MARKET SIZE, BY MANUFACTURERS, 2018-2030 (USD MILLION)
TABLE 292. CHINA BOTANICAL DRUG MARKET SIZE, BY TYPE OF BOTANICAL SOURCE, 2018-2030 (USD MILLION)
TABLE 293. CHINA BOTANICAL DRUG MARKET SIZE, BY FUNGAL SOURCE, 2018-2030 (USD MILLION)
TABLE 294. CHINA BOTANICAL DRUG MARKET SIZE, BY MARINE SOURCE, 2018-2030 (USD MILLION)
TABLE 295. CHINA BOTANICAL DRUG MARKET SIZE, BY PLANT SOURCE, 2018-2030 (USD MILLION)
TABLE 296. CHINA BOTANICAL DRUG MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 297. CHINA BOTANICAL DRUG MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 298. CHINA BOTANICAL DRUG MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 299. CHINA BOTANICAL DRUG MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 300. CHINA BOTANICAL DRUG MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 301. CHINA BOTANICAL DRUG MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
TABLE 302. CHINA BOTANICAL DRUG MARKET SIZE, BY CARDIOVASCULAR HEALTH, 2018-2030 (USD MILLION)
TABLE 303. CHINA BOTANICAL DRUG MARKET SIZE, BY CHRONIC PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 304. CHINA BOTANICAL DRUG MARKET SIZE, BY FORMULA DERIVATIVE, 2018-2030 (USD MILLION)
TABLE 305. CHINA BOTANICAL DRUG MARKET SIZE, BY ESSENTIAL OILS, 2018-2030 (USD MILLION)
TABLE 306. CHINA BOTANICAL DRUG MARKET SIZE, BY EXTRACT, 2018-2030 (USD MILLION)
TABLE 307. CHINA BOTANICAL DRUG MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 308. CHINA BOTANICAL DRUG MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 309. CHINA BOTANICAL DRUG MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 310. CHINA BOTANICAL DRUG MARKET SIZE, BY HEALTH STATUS, 2018-2030 (USD MILLION)
TABLE 311. CHINA BOTANICAL DRUG MARKET SIZE, BY END-USE INDUSTRY, 2018-2030 (USD MILLION)
TABLE 312. CHINA BOTANICAL DRUG MARKET SIZE, BY NUTRACEUTICALS, 2018-2030 (USD MILLION)
TABLE 313. CHINA BOTANICAL DRUG MARKET SIZE, BY PHARMACEUTICAL, 2018-2030 (USD MILLION)
TABLE 314. CHINA BOTANICAL DRUG MARKET SIZE, BY MARKET PARTICIPANTS TYPE, 2018-2030 (USD MILLION)
TABLE 315. CHINA BOTANICAL DRUG MARKET SIZE, BY DISTRIBUTORS, 2018-2030 (USD MILLION)
TABLE 316. CHINA BOTANICAL DRUG MARKET SIZE, BY MANUFACTURERS, 2018-2030 (USD MILLION)
TABLE 317. INDIA BOTANICAL DRUG MARKET SIZE, BY TYPE OF BOTANICAL SOURCE, 2018-2030 (USD MILLION)
TABLE 318. INDIA BOTANICAL DRUG MARKET SIZE, BY FUNGAL SOURCE, 2018-2030 (USD MILLION)
TABLE 319. INDIA BOTANICAL DRUG MARKET SIZE, BY MARINE SOURCE, 2018-2030 (USD MILLION)
TABLE 320. INDIA BOTANICAL DRUG MARKET SIZE, BY PLANT SOURCE, 2018-2030 (USD MILLION)
TABLE 321. INDIA BOTANICAL DRUG MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 322. INDIA BOTANICAL DRUG MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 323. INDIA BOTANICAL DRUG MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 324. INDIA BOTANICAL DRUG MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 325. INDIA BOTANICAL DRUG MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 326. INDIA BOTANICAL DRUG MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
TABLE 327. INDIA BOTANICAL DRUG MARKET SIZE, BY CARDIOVASCULAR HEALTH, 2018-2030 (USD MILLION)
TABLE 328. INDIA BOTANICAL DRUG MARKET SIZE, BY CHRONIC PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 329. INDIA BOTANICAL DRUG MARKET SIZE, BY FORMULA DERIVATIVE, 2018-2030 (USD MILLION)
TABLE 330. INDIA BOTANICAL DRUG MARKET SIZE, BY ESSENTIAL OILS, 2018-2030 (USD MILLION)
TABLE 331. INDIA BOTANICAL DRUG MARKET SIZE, BY EXTRACT, 2018-2030 (USD MILLION)
TABLE 332. INDIA BOTANICAL DRUG MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 333. INDIA BOTANICAL DRUG MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 334. INDIA BOTANICAL DRUG MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 335. INDIA BOTANICAL DRUG MARKET SIZE, BY HEALTH STATUS, 2018-2030 (USD MILLION)
TABLE 336. INDIA BOTANICAL DRUG MARKET SIZE, BY END-USE INDUSTRY, 2018-2030 (USD MILLION)
TABLE 337. INDIA BOTANICAL DRUG MARKET SIZE, BY NUTRACEUTICALS, 2018-2030 (USD MILLION)
TABLE 338. INDIA BOTANICAL DRUG MARKET SIZE, BY PHARMACEUTICAL, 2018-2030 (USD MILLION)
TABLE 339. INDIA BOTANICAL DRUG MARKET SIZE, BY MARKET PARTICIPANTS TYPE, 2018-2030 (USD MILLION)
TABLE 340. INDIA BOTANICAL DRUG MARKET SIZE, BY DISTRIBUTORS, 2018-2030 (USD MILLION)
TABLE 341. INDIA BOTANICAL DRUG MARKET SIZE, BY MANUFACTURERS, 2018-2030 (USD MILLION)
TABLE 342. INDONESIA BOTANICAL DRUG MARKET SIZE, BY TYPE OF BOTANICAL SOURCE, 2018-2030 (USD MILLION)
TABLE 343. INDONESIA BOTANICAL DRUG MARKET SIZE, BY FUNGAL SOURCE, 2018-2030 (USD MILLION)
TABLE 344. INDONESIA BOTANICAL DRUG MARKET SIZE, BY MARINE SOURCE, 2018-2030 (USD MILLION)
TABLE 345. INDONESIA BOTANICAL DRUG MARKET SIZE, BY PLANT SOURCE, 2018-2030 (USD MILLION)
TABLE 346. INDONESIA BOTANICAL DRUG MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 347. INDONESIA BOTANICAL DRUG MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 348. INDONESIA BOTANICAL DRUG MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 349. INDONESIA BOTANICAL DRUG MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 350. INDONESIA BOTANICAL DRUG MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 351. INDONESIA BOTANICAL DRUG MARKET SIZE, BY CANCER TREATMENT, 2018-2030 (USD MILLION)
TABLE 352. INDONESIA BOTANICAL DRUG MARKET SIZE, BY CARDIOVASCULAR HEALTH, 2018-2030 (USD MILLION)
TABLE 353. INDONESIA BOTANICAL DRUG MARKET SIZE, BY CHRONIC PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 354. INDONESIA BOTANICAL DRUG MARKET SIZE, BY FORMULA DERIVATIVE, 2018-2030 (USD MILLION)
TABLE 355. INDONESIA BOTANICAL DRUG MARKET SIZE, BY ESSENTIAL OILS, 2018-2030 (USD MILLION)
TABLE 356. INDONESIA BOTANICAL DRUG MARKET SIZE, BY EXTRACT, 2018-2030 (USD MILLION)
TABLE 357. INDONESIA BOTANICAL DRUG MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-203

Companies Mentioned

  • Aphios Corporation
  • Botanix Pharmaceuticals Ltd
  • CanniMed Therapeutics Inc.
  • Cardiol Therapeutics Inc.
  • CV Sciences, Inc.
  • Ecofibre Limited
  • EcoGen Laboratories
  • Emerald Health Pharmaceuticals
  • GB Sciences, Inc.
  • GW Pharmaceuticals plc
  • HempMeds
  • InMed Pharmaceuticals Inc.
  • Jazz Pharmaceuticals plc
  • Lexaria Bioscience Corp.
  • MediPharm Labs Corp.
  • PhytoTech Therapeutics Ltd.
  • Tetra Bio-Pharma Inc.
  • Tikun Olam Ltd.
  • Veritas Pharma Inc.
  • Zynerba Pharmaceuticals, Inc.

Methodology

Loading
LOADING...

Related Topics

Related Reports

Botanical Drug Market by Type, Source, Therapeutic Application, Formulation, End User, Route Of Administration - Global Forecast 2025-2030 - Product Image

Botanical Drug Market by Type, Source, Therapeutic Application, Formulation, End User, Route Of Administration - Global Forecast 2025-2030

  • Report
  • 191 Pages
  • Global
From
Botanical & Plant Derived Drug Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type - Product Image

Botanical & Plant Derived Drug Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type

  • Report
  • 77 Pages
  • Global
From
Botanical and Plant-derived Drugs Market 2025-2029 - Product Image

Botanical and Plant-derived Drugs Market 2025-2029

  • Report
  • 207 Pages
  • Global
From
Equine Pharmaceuticals & Supplements Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Equine Pharmaceuticals & Supplements Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 180 Pages
  • Global
From
Global Specialty Pharmaceutical Partnering Terms and Agreements 2019-2024 - Product Image

Global Specialty Pharmaceutical Partnering Terms and Agreements 2019-2024

  • Report
  • 750 Pages
  • Global
From

About the Botanical Drug Market

The Botanical Drug market is a subset of the Pharmaceutical industry, focusing on the development and commercialization of drugs derived from plants. Botanical drugs are typically derived from natural sources, such as herbs, roots, and other plant-based materials. These drugs are often used to treat a variety of conditions, including chronic pain, inflammation, and neurological disorders. Botanical drugs are typically administered orally, and may also be used in combination with other drugs. The Botanical Drug market is highly regulated, with stringent safety and efficacy standards in place to ensure the safety of patients. Additionally, the market is subject to a variety of government regulations, including those related to the manufacturing and distribution of botanical drugs. Some companies in the Botanical Drug market include PhytoCeutica, Inc., PhytoTech Therapeutics, and PhytoHealth Corporation. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.